SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), an immuno-oncology
company developing cancer stem cell-related therapeutics, today announced that
it has been granted Orphan Drug designation by the U.S. Food and Drug
Administration (FDA) for the use of tigecycline in the treatment of acute
myeloid leukemia (AML). 


Orphan Drug designation is granted to therapeutics treating rare diseases
affecting less than 200,000 people in the U.S. The designation entitles the
sponsor to seven years of market exclusivity as well as opportunities for
additional funding and expert protocol assistance.


"Orphan Drug status significantly enhances the commercial potential of
tigecycline in AML, a disease which is notoriously difficult to treat," said the
company's Vice President, Drug Development, Dr. Penka Petrova. "Through its
unique mechanism of action and synergy with existing AML therapies, tigecycline
has the potential to positively impact the standard of care in this disease."


The company's program is based on Dr. Aaron Schimmer's published findings that
tigecycline, an FDA-approved antibiotic, selectively targets leukemia cells and
leukemic stem cells by inhibiting mitochondrial protein synthesis and thus
shutting down the cells' energy supply. A Phase I Canadian and U.S. multicenter
dose-escalation clinical trial in patients with relapsed or refractory AML is
nearing completion.


"The Orphan Drug designation covers tigecycline as an active ingredient and is
independent of the drug formulation," added Dr. Bob Uger, the company's Chief
Scientific Officer. "We are investigating improved formulations of tigecycline,
which we believe will be critical for the commercialization of this technology."


About Cancer Stem Cells:

The cancer stem cell (CSC) concept postulates that the growth of tumors is
driven by a rare population of dedicated cells that have stem cell-like
properties, including self- renewal. While the bulk of a tumor consists of
rapidly proliferating cells and differentiated cells, neither of which is
capable of self-renewal, a small population of CSCs provides for long-term
maintenance of the cancer. Although the CSC concept was first postulated in the
1960s, it wasn't until 1994 that proof of their existence was demonstrated, when
Dr. John Dick and colleagues in Toronto isolated CSCs (known as leukemic stem
cells, or LSCs) from bulk acute myeloid leukemia cells. More recently, CSCs have
been identified in many other human malignancies, including solid tumors such as
bladder, brain, breast, colon, ovarian and prostate cancers. There is
accumulating evidence that CSCs are resistant to conventional chemotherapies and
radiation. Thus, CSCs are thought to be responsible for a phenomenon well known
to oncologists: most patients will experience an initial response to
conventional chemotherapies but will ultimately relapse. To cure cancer CSCs
need to be destroyed, but the current armament of therapies is poorly equipped
to do so.


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is an immuno-oncology company advancing
cancer stem cell discoveries into novel and innovative cancer therapies.
Building on over half a century of leading and groundbreaking Canadian stem cell
research, the company is supported by established links to a group of prominent
Toronto academic research institutes and cancer treatment centers, representing
one of the world's most acclaimed cancer research hubs. The Company has two
premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb),
which target two key immunoregulatory pathways that tumor cells exploit to evade
the host immune system. SIRPaFc is an antibody-like fusion protein that blocks
the activity of CD47, a molecule that is upregulated on cancer stem cells in AML
and several other tumors. The CD200 mAb is a fully human monoclonal antibody
that blocks the activity of CD200, an immunosuppressive molecule that is
overexpressed by many hematopoietic and solid tumors. SCT's clinical stage
programs include the recently in-licensed program focused on the structure of
tigecycline, which is currently being evaluated in a multi-centre Phase I study
in patients with acute myeloid leukemia (AML), as well as TTI-1612, a non-
cancer stem cell asset that recently completed a 28-patient Phase I trial in
interstitial cystitis ("IC") patients. For more information, visit:
www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact:
ProActive Capital
Jeff Ramson/Kirin Smith
+1 646-863-6519
jramson@proactivecapital.com
ksmith@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024